EWTX Overview
Upcoming Projects (EWTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (EWTX)
-
A Second Opinion: Examining Edgewise Therapeutics Phase 2 CIRRUS-HCM Clinical Trial Data on EDG-7500 for Hypertrophic Cardiomyopathy
Tickers: EWTX, CYTK, BMS
Executed On: Apr 04, 2025 at 03:30 PM EDT -
Examining Edgewise Therapeutics Phase 2 CIRRUS-HCM Clinical Trial Data on EDG-7500 for Hypertrophic Cardiomyopathy
Tickers: EWTX, CYTK, BMS
Executed On: Apr 04, 2025 at 09:00 AM EDT -
Examining the Topline Results from the CANYON Phase 2 Trial of Sevasemten in Becker Muscular Dystrophy
Ticker: EWTX
Executed On: Dec 19, 2024 at 05:00 PM EST -
Looking at Edgewise Therapeutics Phase 1 & 2 CIRRUS-HCM Development Program Update of EDG-7500 for Hypertrophic Cardiomyopathy
Ticker: EWTX
Executed On: Sep 26, 2024 at 09:00 AM EDT -
A Second Look: Discussing the results from Edgewise Therapeutics ARCH study of EDG-5506, a myofiber type II myosin inhibitor for patients with Becker Muscular Dystrophy (BMD).
Ticker: EWTX
Executed On: Feb 29, 2024 at 10:30 AM EST -
Discussing the results from Edgewise Therapeutics ARCH study of EDG-5506, a myofiber type II myosin inhibitor for patients with Becker Muscular Dystrophy (BMD).
Ticker: EWTX
Executed On: Feb 15, 2024 at 01:15 PM EST
Expired Projects (EWTX)
-
Examining the Phase 2 CANYON Trial Results for Sevasemten (EDG-5506) in Becker Muscular Dystrophy from Edgewise Therapeutics (EWTX)
Ticker: EWTX
Execute By: Feb 28, 2025 -
Examination of Edgewise Therapeutics’ Pipeline for Rare Muscle Disorders
Ticker: EWTX
Execute By: Jul 31, 2021
Upcoming & Overdue Catalysts (EWTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (EWTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
